Investor · 1 deal
London
Every published round Wellcome Trust took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Elastagen Pty Ltd | Series B | Jan 2016 | $13m | Participant | GBS Ventures, Brandon Capital portfolio |
Companies Wellcome Trust has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Elastagen Pty Ltd | Jan 2016, Series B | 1 | 0 |
Fund closes reported for Wellcome Trust, as distinct from the investments it has made.
Companies Wellcome Trust has backed that another company then bought. An exit for the holding, not a deal Wellcome Trust did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Elastagen Pty Ltd | Allergan plc | Acquisition | 7 Feb 2018 | $350m |
Stories naming Wellcome Trust. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Startup Daily·Startup Daily·Startup Daily
Cell Innovation Partners invested A$1 million in Sydney biotech Elastagen within a second close of its A$14 million Series B, with AMOREPACIFIC Ventures, Korea Investment Partners and the Wellcome Trust also joining the round.
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.